Finance

Lists
BIOCON:NSE
Biocon Ltd
₹350,60
-0,11%
(-0,40) 1D
14 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
₹353,00
High
₹353,00
Low
₹347,00
Mkt. cap
571,07 mjd
Avg. vol.
3,11 m
Volume
3,38 m
Dividend
0,14%
Quarterly dividend
₹0,13
Ex-dividend date
03 Jul. 2026
P/E ratio
103,80
52-wk high
₹447,15
52-wk low
₹337,70
EPS
₹3,38
Shares outstanding
600,00 m
No. of employees
16 k
Open
₹353,00
High
₹353,00
Low
₹347,00
Mkt. cap
571,07 mjd
Avg. vol.
3,11 m
Volume
3,38 m
Dividend
0,14%
Quarterly dividend
₹0,13
Ex-dividend date
03 Jul. 2026
P/E ratio
103,80
52-wk high
₹447,15
52-wk low
₹337,70
EPS
₹3,38
Shares outstanding
600,00 m
No. of employees
16 k
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16,4 k
Founded29 Nov. 1978
HeadquartersBangalore, Karnataka, Indië
Sector-
Websitebiocon.com
Last report
06 Aug. 2026
Fiscal period
Q1 2027
₹0,95 / ₹1,09
-12,68%miss
Revenue / Est. (INR)
43,36 mjd / 44,74 mjd
-3,08%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
42,96 mjd
41,73 mjd
45,17 mjd
43,36 mjd
Cost of goods sold
17,72 mjd
13,39 mjd
23,69 mjd
14,68 mjd
Cost of revenue
17,72 mjd
13,39 mjd
23,69 mjd
14,68 mjd
Research and development expenses
-132,00 m
-531,00 m
-128,00 m
-16,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,59 mjd
8,75 mjd
13,28 mjd
9,16 mjd
Operating expense
21,18 mjd
25,16 mjd
14,45 mjd
25,69 mjd
Total operating expenses
38,90 mjd
38,55 mjd
38,14 mjd
40,36 mjd
Operating income
4,05 mjd
3,18 mjd
7,03 mjd
3,00 mjd
Other non operating income
94,00 m
1,17 mjd
-2,52 mjd
545,00 m
EBT including unusual items
1,71 mjd
-678,00 m
2,48 mjd
1,28 mjd
EBT excluding unusual items
1,23 mjd
2,26 mjd
1,80 mjd
1,41 mjd
Income tax expense
385,00 m
-160,00 m
489,00 m
-92,00 m
Effective tax rate
22,48%
23,60%
19,76%
-7,21%
Other operating expenses
6,72 mjd
11,78 mjd
-4,12 mjd
11,07 mjd
Net income
845,00 m
1,44 mjd
1,26 mjd
1,41 mjd
Net profit margin
1,97%
3,45%
2,79%
3,25%
Earnings per share
0,72
2,74
1,27
0,95
Interest and investment income
235,00 m
-
1,15 mjd
-
Interest expense
-2,72 mjd
-2,10 mjd
-2,06 mjd
-2,13 mjd
Net interest expenses
-2,49 mjd
-2,10 mjd
-906,00 m
-2,13 mjd
Depreciation and amortization charges
4,73 mjd
5,15 mjd
5,13 mjd
5,47 mjd
EBITDA
8,69 mjd
7,13 mjd
11,62 mjd
7,59 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme